Eagle Wealth Strategies LLC Has $726,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

Eagle Wealth Strategies LLC trimmed its position in Boston Scientific Co. (NYSE:BSX) by 6.2% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 8,662 shares of the medical equipment provider’s stock after selling 572 shares during the period. Boston Scientific comprises approximately 0.5% of Eagle Wealth Strategies LLC’s holdings, making the stock its 22nd largest holding. Eagle Wealth Strategies LLC’s holdings in Boston Scientific were worth $726,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Triad Wealth Partners LLC acquired a new position in shares of Boston Scientific in the second quarter worth about $26,000. First Foundation Advisors acquired a new position in shares of Boston Scientific in the first quarter worth about $25,000. Eagle Bay Advisors LLC boosted its holdings in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 309 shares during the period. Andra AP fonden acquired a new position in shares of Boston Scientific in the second quarter worth about $29,000. Finally, Lynx Investment Advisory acquired a new position in shares of Boston Scientific in the second quarter worth about $30,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Trading Down 0.3 %

NYSE:BSX traded down $0.24 on Wednesday, hitting $85.60. 1,407,291 shares of the stock were exchanged, compared to its average volume of 5,950,634. The stock has a market capitalization of $125.58 billion, a price-to-earnings ratio of 72.13, a P/E/G ratio of 2.78 and a beta of 0.80. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $86.09. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.61. The company’s 50-day moving average price is $80.48 and its 200 day moving average price is $76.16.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. The firm had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The company’s quarterly revenue was up 14.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.53 EPS. On average, equities research analysts forecast that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at $3,061,135.60. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares of the company’s stock, valued at approximately $133,046,484.48. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 316,253 shares of company stock valued at $26,714,298. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Canaccord Genuity Group raised their price target on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Truist Financial raised their price target on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. BTIG Research raised their price target on shares of Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a report on Monday, July 15th. TD Cowen raised their price target on shares of Boston Scientific from $77.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, July 16th. Finally, Raymond James raised their price target on shares of Boston Scientific from $91.00 to $94.00 and gave the stock a “strong-buy” rating in a report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $87.60.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.